Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognostic Value of Neutrophil-Lymphocyte Ratio (NLR), Absolute Lymphocyte Count (ALC), and Thrombocyte-Lymphocyte Ratio (TLR) in Predicting the Outcomes of Tetralogy of Fallot Primary Repair

NCT05976204 is registered in ClinicalTrials.gov with National Cardiovascular Center Harapan Kita Hospital Indonesia as lead sponsor.

NCT NCT05976204
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05976204 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognostic Value of Neutrophil-Lymphocyte Ratio (NLR), Absolute Lymphocyte Count (ALC), and Thrombocyte-Lymphocyte Ratio (TLR) in Predicting the Outcomes of Tetralogy of Fallot Primary Repair
Lead sponsor
National Cardiovascular Center Harapan Kita Hospital Indonesia
Phase
Observational
Overall status
Completed
Start date
January 1, 2020
Completion date
June 30, 2023
Enrollment
501 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

absolute lymphocyte count, congenital heart disease, neutrophil-lymphocyte ratio, outcome, tetralogy of fallot, thrombocyte-lymphocyte ratio, tof